Analyst firms · Morgan Stanley · GDRX

Morgan Stanley GDRX price target and rating history

GoodRx Holdings Inc. (GDRX) · Technology

Morgan Stanley rates GoodRx Holdings Inc. (GDRX) Equal-Weight with a $19 price target, as of its latest action on Mar 2, 2022. It has published 3 rating actions on GDRX since July 2021, including 0 upgrades and 0 downgrades.

Current rating
Equal-Weight
Price target
$19
Median target, all firms
Too few
Actions on GDRX
3

Morgan Stanley price target on GDRX

$41$30$1920222023202420252026
Morgan Stanley price target on GDRX, each point a stated target, July 2021 to March 2022.

Every Morgan Stanley rating on GDRX

How other firms rate GDRX

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
JefferiesHold$2.75Jan 22, 2026
BarclaysUnderweight$3Dec 9, 2025

Questions about Morgan Stanley and GDRX

What is Morgan Stanley's price target for GDRX?
Morgan Stanley's latest stated price target for GoodRx Holdings Inc. (GDRX) is $19, from its action on Mar 2, 2022.
What is Morgan Stanley's rating on GDRX?
Morgan Stanley rates GDRX Equal-Weight, a neutral rating, as of Mar 2, 2022.
When did Morgan Stanley last change its view on GDRX?
On Mar 2, 2022, Morgan Stanley cuts its price target to $19 from $41, keeps Equal-Weight.

More GDRX rating histories

All Morgan Stanley ratingsGDRX news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.